CureVac, the mRNA Therapy Leader, is invading Moderna’s Homeland!

10/09/2015 - 3 minutes

One more hit to Moderna Therapeutics struck by its German competitor CureVac! The Tübingen-based company just announced the opening of its subsidiary in Boston – hometown of Moderna – and a research collaboration with the U.S. non-profit International AIDS Vaccine Initiative (IAVI) to develop a mRNA-based HIV treatment.

CureVac, today announced the official launch of its U.S. operations in Boston-Cambridge, MA to extend the company’s footprint into the world’s most vibrant biotechnology hub. The U.S. subsidiary will be headed by a former division manager at Novartis Vaccines, and will primarily focus on the business development of CureVac in the U.S. The U.S. presence will also help CureVac to attract a new round of financing to compete with the record $450M collected by Moderna last January.

CureVac’s technology utilizes natural, chemically unmodified mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. To date, CureVac has validated its approach in numerous clinical trials, including an ongoing Phase IIb study in prostate cancer,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member